ClinicalTrials.gg
TerminatedNCT06541444Updated Sep 30, 2026

Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia

An Early Phase 1 interventional study of NK520 in Relapsed/Refractory Acute Myeloid Leukemia, sponsored by Base Therapeutics (Shanghai) Co., Ltd.. Terminated at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Base Therapeutics (Shanghai) Co., Ltd. · Early Phase 1, Interventional, and Treatment

How we know

Why this study was terminated
poor accrual
Updated Sep 30, 2026Now TerminatedPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
2
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 264 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Enrollment
419th of 433
2 · median 50
Started
2024
with 67 others
Phase 1
121 of 473
69 open now
Registered
319th of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 419th largest by enrollment of the 433 interventional ones that give a count, is one of 68 that started in 2024, is one of 121 in phase 1, and was the 319th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

264 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

259 more — sign in →

All 264 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of NK520 in the treatment of relapsed/refractory acute myeloid leukemia. NK520 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.

Read the detailed description

This open label, single-arm study aims to evaluate the efficacy and safety of allogenic natural killer (NK) cells in subjects with relapsed/refractory acute myeloid leukemia. Allogenic NK cells will be infused once a week. After infusion, the investigators will observe the characteristics of dose limited toxicity (DLT), and determine the maximum tolerable dose(MTD). To provide basis for the dosage and treatment plan of cell products in follow-up clinical trials.

03

Conditions studied

  • Relapsed/Refractory Acute Myeloid Leukemia
04

Who can participate

The criteria were revised on the registry on Sep 30, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be between 18 and 75 years;
  2. Diagnostic Criteria:

    Meet the 2016 World Health Organization (WHO) diagnostic criteria for acute myelocytic leukemia (AML), unsuitable for current treatments or patients with AML after ≥2 . The definition of relapsed/refractory acute myeloid leukemia is based on the 2017 Chinese Guidelines for Diagnosis and Treatment:

    1. Relapsed AML: Diagnosis is confirmed when leukemia cells reappear in the peripheral blood or bone marrow blast cells exceed 5% after complete remission (CR) (excluding reasons such as bone marrow regeneration post-consolidation chemotherapy) or there is extramedullary infiltration by leukemia cells;
    2. Refractory AML: Initial cases unresponsive after two cycles of standard regimen treatment; recurrence within 12 months after CR and consolidation therapy; recurrence beyond 12 months with ineffectiveness of conventional chemotherapy; those who have relapsed twice or more; or persistent extramedullary leukemia;
  3. (ECOG) performance status score of 0 to 2;
  4. Expected survival of at least 12 weeks;
  5. Normal Organ Function.

Exclusion criteria

Exclusion Criteria:

  1. Acute promyelocytic leukemia;
  2. Severe bleeding tendency or coagulation disorders, or currently receiving thrombolytic therapy;
  3. Active tuberculosis (TB), currently undergoing anti-TB treatment, or treated for TB within 1 year prior to the study;
  4. (HIV)-infected individuals, or known active syphilis infection;
  5. Use of drugs within 1 week before the first dose, excluding topical, inhaled, or other locally administered , or physiologic doses of systemic glucocorticoids (not exceeding 10 mg/day prednisone equivalent) for allergic reactions or for managing respiratory distress from asthma, (COPD), etc;
  6. Receipt of within 2 weeks before the first dose or planned during the study;
  7. Participation in another clinical trial and receipt of drug within 4 weeks prior to the first dose;
  8. Receipt of immune-modulating drugs (including thymosin, interferons, except for local use to control pleural or ascitic fluid) within 2 weeks prior to the first dose;
  9. At screening, or C viral tests positive according to either:

    • Hepatitis B surface antigen (HBsAg) positive with serum hepatitis B virus- deoxyribonucleic acid (HBV-DNA) titer ≥1×10\^3 copies/mL or above normal limits;
    • virus (HCV) antibody positive;
  10. Any other condition or situation in which the investigator deems the patient unsuitable for participation in this study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Group A(low-dose group)

    NK520: 3×10\^7NK/kg

    Drug: NK520

  • Experimental
    Group B(medium-dose group)

    NK520: 6×10\^7NK/kg

    Drug: NK520

  • Experimental
    Group C(high-dose group)

    NK520: 9×10\^7NK/kg

    Drug: NK520

Interventions

  • DrugNK520

    The number of NK520 cell infused for each dosing will be calculated based on body weight of subject. NK520 should be administered through intravenous infusion once a week, for a total of four times.

    Also known as: genetic modified NK cell

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicity

    To evaluate the DLT during NK520 treatment

    Time frame: From the first dose of NK520 to 4 weeks after last infusion of NK520

  2. Complete Response Rate (CRR)

    Effectiveness Metrics

    Time frame: From the date of first infusion of NK520 up to 104 weeks.

Secondary outcomes

  1. Overall response rate (ORR)

    Effectiveness Metrics

    Time frame: From the date of first infusion of NK520 up to 104 weeks.

  2. Event-Free Survival (EFS)

    Effectiveness Metrics

    Time frame: From date of enrollment up to 104 weeks, or date of progression, or date of death, whichever came first.

  3. Overall Survival (OS)

    Effectiveness Metrics

    Time frame: From date of enrollment up to 104 weeks or date of death, whichever came first.

  4. Duration of Response (DOR)

    Effectiveness Metrics

    Time frame: From the date of enrollment up to 104 weeks

07

Study locations

1 site
  • Shanghai Pudong Hospital
    Shanghai, Shanghai Municipality 201202, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jul 2024 to primary completion in Jun 2025, 11 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Jun 2026 → Jun 2025 and completion Jun 2026 → Jun 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2024
First posted
Aug 7, 2024
StartActual
Jul 1, 2024
Primary completionActual
Jun 1, 2025was Jun 2026
CompletionActual
Jun 1, 2025was Jun 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated poor accrual
changed Sep 30, 2026
Sites
1 site added, 1 site removed
Show site
  • Shanghai Pudong Hospital · Shanghai, China
Show 1 removed
  • Shanghai Pudong Hospital · Shanghai, China
Sep 30, 2026
Primary completion
Jun 1, 2026→Jun 1, 2025 (actual)
Sep 30, 2026
Study completion
Jun 1, 2026→Jun 1, 2025 (actual)
Sep 30, 2026
Enrollment
9 (estimated)→2 (actual)
Sep 30, 2026
Eligibility
1 inclusion criterion edited; 4 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedMeet the 2016 World Health Organization (WHO) diagnostic criteria for acute myelocytic leukemia (AML), unsuitable for current treatments or patients with relapsed/refractory AML after ≥2 lines of therapy. The definition of relapsed/refractory acute myeloid leukemia is based on the 2017 Chinese Guidelines for Diagnosis and Treatment:
Exclusion criteria
  • EditedHuman immunodeficiency virus (HIV)-infected individuals, or known active syphilis infection;
  • EditedUse of immunosuppressive drugs within 1 week before the first dose, excluding topical, inhaled, or other locally administered glucocorticoids, or physiologic doses of systemic glucocorticoids (not exceeding 10 mg/day prednisone equivalent) for allergic reactions or for managing respiratory distress from asthma, chronic obstructive pulmonary disease (COPD), etc;
  • EditedHepatitis B surface antigen (HBsAg) positive with serum hepatitis B virus- deoxyribonucleic acid (HBV-DNA) titer ≥1×10\^3 copies/mL or above normal limits;
  • EditedHepatitis C virus (HCV) antibody positive;
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Recruiting→Terminated
    Why stopped poor accrual
    1 site added, 1 site removed
    Show site
    • Shanghai Pudong Hospital · Shanghai, China
    Show 1 removed
    • Shanghai Pudong Hospital · Shanghai, China
    Primary completion Jun 1, 2026→Jun 1, 2025 (now actual)
    Study completion Jun 1, 2026→Jun 1, 2025 (now actual)
    Enrollment 9 (estimated)→2 (actual)
    Eligibility 1 inclusion criterion edited; 4 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedMeet the 2016 World Health Organization (WHO) diagnostic criteria for acute myelocytic leukemia (AML), unsuitable for current treatments or patients with relapsed/refractory AML after ≥2 lines of therapy. The definition of relapsed/refractory acute myeloid leukemia is based on the 2017 Chinese Guidelines for Diagnosis and Treatment:
    Exclusion criteria
    • EditedHuman immunodeficiency virus (HIV)-infected individuals, or known active syphilis infection;
    • EditedUse of immunosuppressive drugs within 1 week before the first dose, excluding topical, inhaled, or other locally administered glucocorticoids, or physiologic doses of systemic glucocorticoids (not exceeding 10 mg/day prednisone equivalent) for allergic reactions or for managing respiratory distress from asthma, chronic obstructive pulmonary disease (COPD), etc;
    • EditedHepatitis B surface antigen (HBsAg) positive with serum hepatitis B virus- deoxyribonucleic acid (HBV-DNA) titer ≥1×10\^3 copies/mL or above normal limits;
    • EditedHepatitis C virus (HCV) antibody positive;
    + 4 other changes: verification date, description, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06541444
Lead sponsor
Base Therapeutics (Shanghai) Co., Ltd.
Collaborators
Shanghai Pudong Hospital
Responsible party
Sponsor
First posted
Aug 7, 2024
Start date
Jul 1, 2024
Primary completion
Jun 1, 2025
Completion
Jun 1, 2025
Last update
Sep 30, 2026

Study contacts

zhiguo Long
principal investigator · Shanghai Pudong Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion